The Role of Amino Acid Sequences in Peptide Function

Sequence Determines Function

The fundamental principle of peptide biochemistry is that the amino acid sequence — the primary structure — dictates all higher-order structural features and, consequently, biological function. Even a single amino acid substitution can dramatically alter a peptide's receptor binding affinity, selectivity, stability, and activity profile in preclinical models.

Understanding the relationship between sequence and function is critical for researchers working with synthetic peptides, as it informs compound selection, experimental design, and data interpretation.

Primary Structure: The Linear Sequence

The primary structure is simply the linear sequence of amino acids from the N-terminus to the C-terminus. This sequence is determined during synthesis and defines the peptide's identity. For example, BPC-157 is a specific 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from human gastric juice protein. Altering even one residue would create a different compound with potentially different biological properties.

Amino Acid Properties

Each of the 20 standard amino acids brings distinct chemical properties to the peptide chain:

• Hydrophobic residues (Ala, Val, Leu, Ile, Pro, Phe, Trp, Met): Drive folding by clustering in the peptide interior; contribute to membrane interactions
• Polar uncharged residues (Ser, Thr, Asn, Gln, Tyr, Cys): Form hydrogen bonds; participate in receptor contacts
• Positively charged residues (Lys, Arg, His): Engage in electrostatic interactions with negatively charged receptor surfaces or nucleic acids
• Negatively charged residues (Asp, Glu): Form salt bridges; coordinate metal ions
• Special residues — Glycine provides flexibility; Proline introduces rigidity and kinks

Secondary Structure: Local Folding Patterns

The amino acid sequence directs the formation of local structural elements:

• Alpha-helices: Stabilized by hydrogen bonds between backbone C=O and N-H groups four residues apart. Alanine, leucine, and glutamate are strong helix formers; proline and glycine are helix breakers.
• Beta-sheets: Formed by extended peptide strands aligned side-by-side, stabilized by inter-strand hydrogen bonds. Valine, isoleucine, and threonine favor beta-sheet formation.
• Turns and loops: Reverse the direction of the peptide chain. Proline and glycine frequently appear in turns due to their unique conformational properties.

How Sequence Affects Receptor Binding

Peptides exert their biological effects by binding to specific receptors on cell surfaces or within cells. The binding interaction depends on complementarity between the peptide's three-dimensional shape and the receptor's binding pocket.

Consider GLP-1 receptor agonists like Semaglutide: the native GLP-1 peptide sequence has been modified at specific positions to enhance receptor binding affinity, resist enzymatic degradation by DPP-4, and increase half-life through albumin binding. Each modification was guided by structure-activity relationship (SAR) studies that systematically varied the sequence to identify critical pharmacophore elements.

Sequence Modifications for Stability

Researchers have developed numerous sequence-based strategies to enhance peptide stability:

• N-methylation: Replacing backbone amide protons with methyl groups to resist proteolysis
• D-amino acid substitution: Incorporating mirror-image amino acids at protease-sensitive sites
• Cyclization: Forming head-to-tail or side-chain-to-side-chain bonds to constrain conformation and resist degradation
• PEGylation: Attaching polyethylene glycol chains to increase hydrodynamic radius and reduce renal clearance
• Lipidation: Conjugating fatty acid chains (as in Semaglutide) to promote albumin binding and extend half-life

Implications for Research

Understanding sequence-function relationships allows researchers to make informed decisions about which peptide variants to study. When comparing compounds like Tirzepatide (a dual GIP/GLP-1 agonist) with Semaglutide (a selective GLP-1 agonist), the sequence differences directly explain their distinct receptor binding profiles and downstream signaling cascades observed in preclinical models.